Will the Phase 2 trial "OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites" reach primary completion on or before Dec 31, 2027?

Resolves Yes if ClinicalTrials.gov record NCT06856603 (National Medical Research Radiological Centre of the Ministry of Health of Russia) shows an actual primary completion date on or before Dec 31, 2027. Registered date at generation: Dec 31, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Dec 31, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.